Medline Targets Nasdaq Debut with 179M Share IPO

TL;DR

**Medline's IPO is a strong buy, backed by massive institutional interest and a clear path to debt reduction and growth.**

AI Summary

Medline Inc. is launching its initial public offering (IPO) of 179,000,000 shares of Class A common stock, with an expected price range of $26.00 to $30.00 per share. The company plans to list its shares on the Nasdaq Global Select Market under the ticker "MDLN." Proceeds from the offering will be used to acquire newly issued Common Units from Medline Holdings, LP, which will then use the funds for indebtedness repayment, general corporate purposes, and covering offering expenses. Notably, members of the Mills Family have indicated an interest in purchasing up to $250 million in shares, while cornerstone investors, including Baillie Gifford Overseas Limited and Capital Research Global Investors, have indicated interest in purchasing up to an aggregate of $2,350 million in shares. Post-IPO, Medline Inc. will operate as a holding company, controlling Medline Holdings, LP and its subsidiaries. The company will have a dual-class stock structure, with Class A and Class B common stock, each carrying one vote per share, and Class B stock held by Continuing Common Unitholders.

Why It Matters

This S-1/A filing signals Medline's transition to a public entity, offering investors a chance to own a piece of a major healthcare supply chain player. The significant interest from cornerstone investors, totaling $2.35 billion, underscores strong institutional confidence, potentially driving a robust IPO. For employees, the IPO could unlock equity value, while customers might see enhanced service capabilities from a better-capitalized Medline. In a competitive landscape with other medical distributors, this capital infusion could strengthen Medline's market position and expand its 'Prime Vendor' model.

Risk Assessment

Risk Level: medium — The offering involves a dual-class stock structure where Class B common stock, held by Continuing Common Unitholders, will have equal voting rights to Class A, potentially concentrating control. Additionally, the filing states that the initial public offering price is expected to be between $26.00 and $30.00 per share, but there is no prior public market for the common stock, introducing price discovery risk.

Analyst Insight

Investors should closely monitor the final IPO pricing and the allocation to cornerstone investors, as their substantial commitments suggest confidence. Consider Medline's long-term growth potential in the healthcare supply chain, especially its 'Prime Vendor' model, but be aware of the concentrated voting power of Class B shareholders.

Financial Highlights

debt To Equity

1.31

revenue

$18,368 million

operating Margin

8.4%

total Assets

$16,747 million

total Debt

$9,467 million

net Income

$1,260 million

eps

$13.77

gross Margin

20.5%

cash Position

$1,066 million

revenue Growth

+11.0%

Key Numbers

• 179,000,000 — Shares of Class A common stock offered (Initial public offering quantity)
• $26.00 — Low end of expected IPO price range per share (Expected initial public offering price)
• $30.00 — High end of expected IPO price range per share (Expected initial public offering price)
• $250 million — Indicated interest from Mills Family (Potential share purchase by existing owners)
• $2,350 million — Aggregate indicated interest from cornerstone investors (Significant institutional demand for shares)
• 26,850,000 — Additional shares underwriters option to purchase (Greenshoe option for Class A common stock)
• 32 — Page number for Risk Factors (Location of detailed risk disclosures)
• 2025-12-08T00:00:00Z — Filing date of S-1/A (Date of the latest amendment to the registration statement)

Key Players & Entities

• Medline Inc. (company) — Registrant for S-1/A IPO
• Medline Holdings, LP (company) — Predecessor for financial reporting, controlled by Medline Inc. post-IPO
• James Boyle (person) — Chief Executive Officer of Medline Inc.
• Alex Liberman (person) — Chief Legal Officer of Medline Inc.
• Mills Family (person) — Pre-IPO equity holders, indicated interest in purchasing up to $250 million in shares
• Baillie Gifford Overseas Limited (company) — Cornerstone investor, indicated interest in purchasing shares
• Capital Research Global Investors (company) — Cornerstone investor, indicated interest in purchasing shares
• Nasdaq Global Select Market (regulator) — Intended listing exchange for MDLN
• Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing
• Goldman Sachs & Co. LLC (company) — Global Coordinator and Joint Bookrunning Manager for the IPO

FAQ

Risk Factors

• Competition and Market Saturation [high — market]: Medline operates in a highly competitive market with numerous players, including large national distributors, group purchasing organizations (GPOs), and smaller regional distributors. Increased competition could lead to pricing pressures, reduced market share, and lower profitability. The company faces risks from competitors with greater financial resources or more established relationships with healthcare providers.
• Healthcare Regulatory Changes [high — regulatory]: The healthcare industry is subject to extensive and evolving government regulation, including Medicare and Medicaid reimbursement policies, fraud and abuse laws, and regulations related to product safety and efficacy. Changes in these regulations could adversely affect Medline's business, financial condition, and results of operations. For example, shifts in reimbursement models could impact demand for the products Medline distributes.
• Supply Chain Disruptions [medium — operational]: Medline relies on a complex global supply chain to source and distribute its products. Disruptions due to geopolitical events, natural disasters, pandemics, or the financial instability of suppliers could impact product availability and increase costs. The company's ability to manage inventory effectively and maintain relationships with key suppliers is critical.
• Indebtedness and Leverage [high — financial]: Medline has a significant amount of indebtedness, as detailed in the 'Description of Certain Indebtedness' section. The company's ability to service its debt obligations depends on its future financial performance and its ability to generate sufficient cash flow. High leverage could limit its financial flexibility and ability to fund operations or pursue strategic opportunities.
• Product Liability and Recalls [medium — legal]: As a distributor of medical supplies and devices, Medline faces potential liability related to the safety and efficacy of the products it sells. Product recalls or claims of defective products could result in significant financial costs, reputational damage, and legal liabilities. The company's indemnification agreements with manufacturers may not fully protect it from all such risks.

Industry Context

Medline operates within the highly competitive medical supplies distribution industry, serving a broad range of healthcare providers. Key trends include consolidation among distributors and providers, increasing demand for cost-efficiency, and the growing importance of technology in supply chain management. The industry is also heavily influenced by healthcare policy and reimbursement rates.

Regulatory Implications

The company faces significant regulatory scrutiny inherent in the healthcare sector. Compliance with laws related to healthcare fraud and abuse, product safety, and data privacy is critical. Changes in government healthcare policy, such as Medicare/Medicaid reimbursement adjustments, could materially impact Medline's revenue and profitability.

What Investors Should Do

1. Evaluate the company's leverage and debt repayment strategy.
2. Analyze the competitive landscape and Medline's market position.
3. Assess the impact of potential regulatory changes in the healthcare sector.
4. Consider the implications of the dual-class stock structure.

Key Dates

• 2022-12-08: Filing of S-1/A Amendment — This is the latest amendment to the registration statement, providing updated financial information and disclosures for the IPO.

Glossary

Class A Common Stock

A class of common stock being offered in the IPO, carrying one vote per share. (Represents the shares investors can purchase in the public offering.)

Class B Common Stock

A class of common stock held by Continuing Common Unitholders, also carrying one vote per share. (Indicates a dual-class structure that may give existing holders disproportionate voting control post-IPO.)

Medline Holdings, LP

The operating partnership that holds Medline's subsidiaries and assets. (Medline Inc. will operate as a holding company controlling this entity, which is central to the business operations.)

Common Units

Units of ownership in Medline Holdings, LP. (The IPO proceeds will be used to acquire newly issued Common Units from Medline Holdings, LP.)

Cornerstone Investors

Large institutional investors who commit to purchasing a significant portion of shares in an IPO. (Indicated interest from Baillie Gifford and Capital Research Global Investors signals strong institutional demand and confidence.)

Greenshoe Option

An option granted to underwriters to purchase additional shares from the issuer or selling shareholders at the IPO price. (Allows underwriters to stabilize the stock price after trading begins and meet excess demand.)

Year-Over-Year Comparison

The S-1/A filing provides updated financial information compared to previous filings. Revenue has shown growth, increasing by 11.0% to $18,368 million, and net income stands at $1,260 million. While specific year-over-year comparisons for margins and EPS are not directly available in this summary, the reported figures indicate a substantial and profitable operation. New risks related to the IPO process itself and the company's capital structure post-offering are detailed.

Key Financial Figures

• $26.00 — ial public offering price to be between $26.00 and $30.00 per share of Class A common
• $30.00 — offering price to be between $26.00 and $30.00 per share of Class A common stock. We h
• $250 million — est in purchasing up to an aggregate of $250 million in shares of our Class A common stock i
• $2,350 million — est in purchasing up to an aggregate of $2,350 million in shares of our Class A common stock i
• $28.00 — to be sold in this offering are sold at $28.00 per share, which is the midpoint of the

Filing Documents

• d55108ds1a.htm (S-1/A) — 4167KB
• d55108dex51.htm (EX-5.1) — 10KB
• d55108dex231.htm (EX-23.1) — 1KB
• d55108dexfilingfees.htm (EX-FILING FEES) — 19KB
• g55108g00a01.jpg (GRAPHIC) — 826KB
• g55108g00a02.jpg (GRAPHIC) — 434KB
• g55108g00a03.jpg (GRAPHIC) — 328KB
• g55108g00a08.jpg (GRAPHIC) — 498KB
• g55108g00a09.jpg (GRAPHIC) — 486KB
• g55108g00a23.jpg (GRAPHIC) — 256KB
• g55108g00a74.jpg (GRAPHIC) — 50KB
• g55108g00a75.jpg (GRAPHIC) — 164KB
• g55108g00w02.jpg (GRAPHIC) — 111KB
• g55108g01g01.jpg (GRAPHIC) — 60KB
• g55108g02g02.jpg (GRAPHIC) — 60KB
• g55108g04w04.jpg (GRAPHIC) — 123KB
• g55108g10w00.jpg (GRAPHIC) — 148KB
• g55108g12w00.jpg (GRAPHIC) — 187KB
• g55108g12w80.jpg (GRAPHIC) — 169KB
• g55108g13w30.jpg (GRAPHIC) — 176KB
• g55108g13w61.jpg (GRAPHIC) — 596KB
• g55108g13w62.jpg (GRAPHIC) — 47KB
• g55108g13w63.jpg (GRAPHIC) — 40KB
• g55108g14w00.jpg (GRAPHIC) — 70KB
• g55108g14w10.jpg (GRAPHIC) — 83KB
• g55108g21f02.jpg (GRAPHIC) — 123KB
• g55108g53h11.jpg (GRAPHIC) — 223KB
• g55108g97e08.jpg (GRAPHIC) — 204KB
• 0001193125-25-311099.txt ( ) — 11696KB
• d55108dexfilingfees_htm.xml (XML) — 6KB

Forward-Looking Statements

Forward-Looking Statements 70 Market and Industry Data 72 Trademarks, Trade Names, and Service Marks 72 Organizational Structure 74

Use of Proceeds

Use of Proceeds 83 Dividend Policy 84 Capitalization 86

Dilution

Dilution 88 Unaudited Pro Forma Condensed Consolidated Financial Information 90

Management's Discussion and Analysis of Financial Condition and Results

Management's Discussion and Analysis of Financial Condition and Results of Operations 103

Business

Business 136 Management 164 Certain Relationships and Related Person Transactions 208 Principal Stockholders 217 Description of Certain Indebtedness 222

Description of Capital Stock

Description of Capital Stock 230 Certain U.S. Federal Income Tax Consequences to Non-U.S. Holders 239 Shares Eligible for Future Sale 242 Underwriting (Conflicts of Interest) 245 Legal Matters 260 Experts 260 Where You Can Find More Information 260 Index to Financial Statements F-1 Neither we nor the underwriters have authorized anyone to provide you with information different from that contained in this prospectus, any amendment or supplement to this prospectus, or any free writing prospectus prepared by us or authorized to be provided on our behalf. Neither we nor the underwriters take any responsibility for, or can provide any assurance as to the reliability of, any information other than the information in this prospectus, any amendment or supplement to this prospectus, or any free writing prospectus prepared by us or authorized to be provided on our behalf. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our Class A common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. We and the underwriters are offering to sell, and seeking offers to buy, shares of our Class A common stock only in jurisdictions where offers and sales are permitted. Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of Class A common stock and the distribution of this prospectus outside of the United States. Through and including , 202 (the 25th day after the date of this prospectus), all dealers effecting transactions i

View Full Filing

View this S-1/A filing on SEC EDGAR